niacinamide has been researched along with Adenocarcinoma, Clear Cell in 5 studies
nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.
Adenocarcinoma, Clear Cell: An adenocarcinoma characterized by the presence of varying combinations of clear and hobnail-shaped tumor cells. There are three predominant patterns described as tubulocystic, solid, and papillary. These tumors, usually located in the female reproductive organs, have been seen more frequently in young women since 1970 as a result of the association with intrauterine exposure to diethylstilbestrol. (From Holland et al., Cancer Medicine, 3d ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Sorafenib was administered orally to mice bearing subcutaneous (SC, ectopic) or sub-renal capsule (SRC, orthotopic) tumors of murine (Renca) or human (786-O) RCC." | 5.34 | Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models. ( Adnane, J; Bortolon, E; Carter, CA; Chang, YS; Chen, C; Henderson, A; Ichetovkin, M; Levy, J; Lynch, M; McNabola, A; Taylor, IC; Trail, PA; Wilhelm, S; Wilkie, D; Xue, D, 2007) |
| "Sorafenib is an oral multikinase inhibitor targeting Raf and other kinases." | 1.40 | Two cases of recurrent ovarian clear cell carcinoma treated with sorafenib. ( Baba, T; Konishi, I; Koshiyama, M; Matsumura, N; Yamaguchi, K; Yoshioka, Y, 2014) |
| "Sorafenib (Nexavar) is a multi-kinase inhibitor that was developed as an inhibitor of RAF-1, in the ERK1/2 pathway, but which was subsequently shown to inhibit class III tyrosine kinase receptors." | 1.40 | Multi-kinase inhibition in ovarian cancer. ( Dent, P, 2014) |
| "Microarray datasets of ovarian cancer cell lines and cancer tissues were analyzed using bioinformatic tools." | 1.36 | Sorafenib efficacy in ovarian clear cell carcinoma revealed by transcriptome profiling. ( Baba, T; Hamanishi, J; Kang, HS; Konishi, I; Mandai, M; Matsui, S; Matsumura, N; Mori, S; Murphy, SK; Okamoto, T; Oura, T; Yamaguchi, K; Yamamura, S, 2010) |
| "Sorafenib was administered orally to mice bearing subcutaneous (SC, ectopic) or sub-renal capsule (SRC, orthotopic) tumors of murine (Renca) or human (786-O) RCC." | 1.34 | Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models. ( Adnane, J; Bortolon, E; Carter, CA; Chang, YS; Chen, C; Henderson, A; Ichetovkin, M; Levy, J; Lynch, M; McNabola, A; Taylor, IC; Trail, PA; Wilhelm, S; Wilkie, D; Xue, D, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Koshiyama, M | 1 |
| Matsumura, N | 2 |
| Baba, T | 2 |
| Yamaguchi, K | 2 |
| Yoshioka, Y | 1 |
| Konishi, I | 2 |
| Dent, P | 1 |
| Mandai, M | 1 |
| Okamoto, T | 1 |
| Yamamura, S | 1 |
| Oura, T | 1 |
| Hamanishi, J | 1 |
| Kang, HS | 1 |
| Matsui, S | 1 |
| Mori, S | 1 |
| Murphy, SK | 1 |
| Dranitsaris, G | 1 |
| Vincent, MD | 1 |
| Yu, J | 1 |
| Huang, L | 1 |
| Fang, F | 1 |
| Lacouture, ME | 1 |
| Chang, YS | 1 |
| Adnane, J | 1 |
| Trail, PA | 1 |
| Levy, J | 1 |
| Henderson, A | 1 |
| Xue, D | 1 |
| Bortolon, E | 1 |
| Ichetovkin, M | 1 |
| Chen, C | 1 |
| McNabola, A | 1 |
| Wilkie, D | 1 |
| Carter, CA | 1 |
| Taylor, IC | 1 |
| Lynch, M | 1 |
| Wilhelm, S | 1 |
1 trial available for niacinamide and Adenocarcinoma, Clear Cell
| Article | Year |
|---|---|
Development and validation of a prediction index for hand-foot skin reaction in cancer patients receiving sorafenib.
Topics: Adenocarcinoma, Clear Cell; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Age | 2012 |
4 other studies available for niacinamide and Adenocarcinoma, Clear Cell
| Article | Year |
|---|---|
Two cases of recurrent ovarian clear cell carcinoma treated with sorafenib.
Topics: Adenocarcinoma, Clear Cell; Antineoplastic Agents; Female; Humans; Middle Aged; Neoplasm Recurrence, | 2014 |
Multi-kinase inhibition in ovarian cancer.
Topics: Adenocarcinoma, Clear Cell; Antineoplastic Agents; Female; Humans; Neoplasm Recurrence, Local; Niaci | 2014 |
Sorafenib efficacy in ovarian clear cell carcinoma revealed by transcriptome profiling.
Topics: Adenocarcinoma, Clear Cell; Animals; Antineoplastic Agents; Benzenesulfonates; Female; Gene Expressi | 2010 |
Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models.
Topics: Actins; Adenocarcinoma, Clear Cell; Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Benzene | 2007 |